Canada markets closed

Clearside Biomedical, Inc. (CLSD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.2500-0.1000 (-7.41%)
At close: 04:00PM EDT
1.2899 +0.04 (+3.19%)
After hours: 04:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.3500
Open1.3000
Bid1.2200 x 100
Ask1.2900 x 100
Day's Range1.2100 - 1.3100
52 Week Range0.6500 - 2.1200
Volume286,101
Avg. Volume377,546
Market Cap93.414M
Beta (5Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

    - Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions -- Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results

  • GlobeNewswire

    Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

    ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m. ET in Ne

  • GlobeNewswire

    Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

    ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate u